Medgenics to Present Poster at European Society of Gene & Cell Therapy Congress to Highlight Results from Second-Generation V...
October 23 2013 - 8:15AM
Business Wire
Medgenics, Inc. (NYSEMKT:MDGN)(AIM:MEDU, MEDG) (the
“Company”), the developer of a novel technology for the sustained
production and delivery of therapeutic proteins in patients using
their own tissue, announces that a poster highlighting the
Company’s second-generation EPODURE Biopump™ will be presented at
the European Society of Gene and Cell Therapy Congress, taking
place in Madrid October 25-28.
Posters will be showcased in Poster Reception Halls A-C November
1-3 and will be available for viewing from 9:30 a.m. to 2:30 p.m.
local time. Poster presentations will take place from 10:00 a.m. to
12:00 p.m. The following Medgenics’ poster will be presented during
Poster Session B on Sunday, October 27:
- "Second generation EPODURE Biopump™
markedly extends duration of EPO delivery in mice, could prolong
therapeutic effect in patients,” by Miari, et. al. Poster Number
P146.
EPODURE is an autologous dermal Biopump capable of the sustained
production of therapeutic erythropoietin (“EPO”) in the body using
a small tissue explant from the patient’s own skin and processed to
continuously produce EPO. Each EPODURE Biopump is subsequently
implanted subcutaneously into the patient aiming to provide
continuous delivery of EPO.
About The European Society of Gene and Cell Therapy
(ESGCT)
The European Society of Gene and Cell Therapy (ESGCT) promotes
basic and clinical research in gene therapy, cell therapy and
genetic vaccines by facilitating education, the exchange of
information and technology and by serving as a professional adviser
to stakeholder communities and regulatory bodies in Europe.
About Medgenics
Medgenics is developing and commercializing Biopump™, a
proprietary tissue-based platform technology for the sustained
production and delivery of therapeutic proteins using the patient's
own tissue for the treatment of a range of chronic diseases
including anemia and hepatitis, among others. For more information,
please visit www.medgenics.com.
Forward-looking Statements
This release contains forward-looking statements within the
meaning of Section 27A of the Securities Act of 1933, Section 21E
of the Securities Exchange Act of 1934 and as that term is defined
in the Private Securities Litigation Reform Act of 1995, which
include all statements other than statements of historical fact,
including (without limitation) those regarding the Company's
financial position, its development and business strategy, its
product candidates and the plans and objectives of management for
future operations. The Company intends that such forward-looking
statements be subject to the safe harbors created by such laws.
Forward-looking statements are sometimes identified by their use of
the terms and phrases such as "estimate," "project," "intend,"
"forecast," "anticipate," "plan," "planning, "expect," "believe,"
"will," "will likely," "should," "could," "would," "may" or the
negative of such terms and other comparable terminology. All such
forward-looking statements are based on current expectations and
are subject to risks and uncertainties. Should any of these risks
or uncertainties materialize, or should any of the Company's
assumptions prove incorrect, actual results may differ materially
from those included within these forward-looking statements.
Accordingly, no undue reliance should be placed on these
forward-looking statements, which speak only as of the date made.
The Company expressly disclaims any obligation or undertaking to
disseminate any updates or revisions to any forward-looking
statements contained herein to reflect any change in the Company's
expectations with regard thereto or any change in events,
conditions or circumstances on which any such statements are based.
As a result of these factors, the events described in the
forward-looking statements contained in this release may not
occur.
LHAAnne Marie Fields,
212-838-3777afields@lhai.com@LHA_IR_PRorAbchurch
CommunicationsJoanne Shears/Jamie
Hooper+44-207-398-7719jamie.hooper@abchurch-group.comorOriel
Securities (NOMAD & Joint Broker)Jonathan Senior/Giles
Balleny+44-207710-7617orSVS Securities plc (Joint Broker)Alex
Brearley, +44-207-638-5600
Aevi Genomic Medicine (NASDAQ:GNMX)
Historical Stock Chart
From Sep 2024 to Oct 2024
Aevi Genomic Medicine (NASDAQ:GNMX)
Historical Stock Chart
From Oct 2023 to Oct 2024